Acquired resistance to the TRK inhibitor entrectinib in colorectal cancer

Mariangela Russo1,2,3*, Sandra Misale2*, Ge Wei4*, Giulia Siravegna1,2, Giovanni Crisafulli2, Luca Lazzari1,2, Giorgio Corti2, Giuseppe Rospo2, Luca Novara2, Benedetta Mussolin2, Alice Bartolini2, Nicholas Cam4, Roopal Patel4, Shunqi Yan4, Robert Shoemaker4, Robert Wild4, Federica Di Nicolantonio1,2, Andrea Sartore Bianchi5, Gang Li4, Salvatore Siena5,6, §, Alberto Bardelli1,2, §,#

1University of Torino, Department of Oncology, SP 142, Km 3.95, 10060 Candiolo, Torino, Italy; 2Candiolo Cancer Institute – FPO, IRCCS, Candiolo, Torino, Italy; 3 FIRC Institute of Molecular Oncology (IFOM), Milano, Italy; 4 Ignyta, Inc. San Diego, CA, USA; 5Department of Hematology and Oncology, Niguarda Cancer Center, Ospedale Niguarda Ca’ Granda, Milan, Italy; 6Università degli Studi di Milano, Milan, Italy

* Drs. Russo, Misale and Wei contributed equally to this article; § Drs. Bardelli and Siena are co-senior author; # Address correspondence to:
Alberto Bardelli at: alberto.bardelli@unito.it
University of Torino, Department of Oncology, FPO, IRCCS, SP 142, Km 3.95, Candiolo (TO), ZIP 10060, Italy
Phone: +39-011-9933548

Running Title:
TRKA mutations and resistance to entrectinib in CRC

Key words:
Colorectal, acquired resistance, NTRK1, TRK inhibition, ctDNA

Conflict of interest
Ignyta co-authors are full time employees of Ignyta, and own Ignyta stocks. All the other authors do not have conflict of interest to declare.
Abstract

Entrectinib is a first-in-class pan-TRK kinase inhibitor currently undergoing clinical testing in colorectal cancer and other tumor types. A patient with metastatic colorectal cancer harboring an LMNA-NTRK1 rearrangement displayed a remarkable response to treatment with entrectinib, which was followed by the emergence of resistance. To characterize the molecular bases of the patient’s relapse, circulating tumor DNA (ctDNA) was collected longitudinally during treatment and a tissue biopsy, obtained before entrectinib treatment, was transplanted in mice (xenopatient), which then received the same entrectinib regimen until resistance developed. Genetic profiling of ctDNA and xeno-patient samples showed acquisition of two point mutations in the catalytic domain of NTRK1, p.G595R and p.G667C. Biochemical and pharmacological analysis in multiple preclinical models confirmed that either mutation renders the TRKA kinase insensitive to entrectinib. These findings can be immediately exploited to design next generation TRKA inhibitors.

Significance

We provide proof of principle that analyses of xenopatients (avatar) and liquid biopsies allow the identification of drug resistance mechanisms in parallel with clinical treatment of individual patient. We describe for the first time that p.G595R and p.G667C TRKA mutations drive acquired resistance to entrectinib in colorectal cancers carrying NTRK1 rearrangements.
Introduction

TRK receptors are a family of tyrosine kinases that comprises three members: TRKA, TRKB and TRKC, encoded by the NTRK1 (neurotrophic tyrosine kinase receptor, type 1), NTRK2 and NTRK3 genes, respectively. Genomic rearrangement is the most common mechanism of oncogenic activation for this family of receptors, resulting in sustained cancer cell proliferation through activation of MAPK and AKT downstream pathways (1). Rearrangements of the NTRK1, NTRK2 and NTRK3 genes occur across different tumors including colorectal cancers (CRCs) (2).

Entrectinib (RXDX-101, previously known as NMS-E628) is a potent pan-TRK, ALK, ROS1 inhibitor, currently undergoing phase I clinical trial(3). During treatment with entrectinib a patient with metastatic colorectal cancer harboring an LMNA-NTRK1 rearrangement showed a remarkable response. We reasoned that, as it has been shown for most targeted agents, response to entrectinib might be limited in time due to the emergence of acquired resistance. Nothing is presently known on the mechanisms of resistance to entrectinib and consequently further lines of treatment are not available. We postulated that it might be possible to identify the resistance mechanism(s) while the patient was being treated by analyzing circulating tumor DNA (ctDNA) and developing a xenopatient (avatar).

Results
Acquired resistance to TRKA inhibition in a CRC patient.

A molecular screen identified a genetic rearrangement involving exon 10 of \textit{NTRK1} and exon 11 of the \textit{LMNA} genes\cite{4} in a patient with metastatic colorectal cancer (mCRC) whose disease was intrinsically resistant to 1\textsuperscript{st} line FOLFOX, 2\textsuperscript{nd} line FOLFIRI/cetuximab and 3\textsuperscript{rd} line Irinotecan. We and others have previously reported that CRC cell models harboring \textit{NTRK1} translocations are sensitive to \textit{NTRK1} silencing and to TRKA (protein encoded by \textit{NTRK1} gene) kinase inhibition\cite{5-7}. Based on this, the patient was enrolled in the phase I ALKA clinical trial (EudraCT Number 2012-000148-88) of the pan-TRK kinase inhibitor entrectinib, a first-in-class drug currently undergoing clinical testing\cite{3}. The patient received entrectinib on an intermittent dosing schedule of 4 days on/3 days off for three weeks followed by a week break in every 28-day cycle\cite{4}. Treatment was remarkably effective and well tolerated, leading to a partial response (PR) with 30\% tumor shrinkage of multiple liver metastases that was demonstrated by an early CT scan assessment performed after 30 days of treatment. The clinical response lasted four months, followed by the emergence of drug resistance as evaluated by RECIST (Response Evaluation Criteria in Solid Tumor) progression (Fig. 1 upper panels).

Emergence of \textit{NTRK1} mutations in ctDNA during entrectinib treatment

To unveil the molecular basis of acquired resistance to TRKA inhibition we analyzed circulating tumor DNA (ctDNA), a form of liquid biopsy \cite{8} we
previously optimized to detect and monitor drug resistance in patients treated with targeted agents (9,10).

cTMA extracted from plasma samples collected before treatment initiation and at clinical relapse was subjected to molecular profiling using the IRCC-TARGET panel, an NGS-platform based on 226 cancer related genes (10). Profiling of ctDNA at entrectinib resistance revealed two novel NTRK1 genetic alterations in the kinase domain of the protein, p.G595R and p.G667C, which were not detected in ctDNA obtained before initiation of therapy (Supplementary Tables S1, S2). To monitor the NTRK1 mutated alleles in the plasma of the patient collected through the treatment, droplet digital PCR (ddPCR) (11,12) assays were designed for both mutations. As a mean of tracking the overall disease, a ddPCR assay was also optimized to detect the LMNA-NTRK1 rearrangement in ctDNA.

Longitudinal analysis of plasma revealed that the p.G595R and p.G667C mutated alleles were initially absent in ctDNA but emerged in the circulation as early as 4 weeks upon initiation of treatment with entrectinib (Fig. 1). NTRK1 mutations frequencies continued to increase in ctDNA and peaked when clinical progression was radiologically confirmed (16 weeks after initiation of treatment). The profile of the LMNA-NTRK1 rearrangement in ctDNA paralleled tumor response and resistance to entrectinib (Fig. 1; Supplementary Table S3).

**Secondary resistance to entrectinib in CRC Xenopatient**
To functionally evaluate the mechanistic basis of resistance to entrectinib, a biopsy specimen gathered before initiation of treatment was transplanted subcutaneously in an immunocompromised mouse (xenopatient) (see Supplementary Methods). Upon successful engraftment, the tumor was expanded in multiple mice, which were treated with dosage levels and schedules that matched clinically relevant exposure achievable in patients. Entrectinib induced remarkable tumor shrinkage in the xenopatient while vehicle treated tumors grew exponentially (Fig. 2A). After 3 weeks of drug dosing, one of the tumors treated with entrectinib rapidly developed resistance to TRKA inhibition (Fig. 2A). NGS-based molecular profiling of this resistant sample using the IRCC-TARGET panel unveiled the LMNA-NTRK1 rearrangement peculiar of the patient and the NTRK1 p.G595R mutation, which could not be detected in the untreated tumor (Supplementary Fig. S1A, B; Supplementary Tables S1, S2).

Secondary resistance to entrectinib in cells carrying NTRK1 rearrangements

To assess whether the mechanism of resistance was patient-specific or contingent on the peculiar NTRK1 rearrangements, independent models of acquired resistance to entrectinib were established. The KM12 CRC cell line harbors a distinct genetic rearrangement involving exon 10 of NTRK1 and exon 7 of TPM3 gene (5,7) and is also highly sensitive to entrectinib (Fig. 2B,C). Independent batches of parental (sensitive) KM12 cells were exposed to either acute constant dose (R2) or escalating doses (R1) of entrectinib until resistant derivatives emerged (Fig. 2B,C) (see Supplementary Methods).
Molecular profiling of the cells that became resistant to lower concentrations of entrectinib (30-100 nM) (named KM12 R1) revealed the missense mutation p.G667C in the kinase domain of \textit{NTRK1}, previously identified also in the plasma of the patient (Fig. 2B). When cells were made resistant to a higher doses (1-2 µM) of the drug (named KM12 R2), the \textit{NTRK1} p.G595R alteration was detected (Fig. 2C). The experiment was repeated multiple times, the two mutations were never concomitantly detected in the same resistant populations indicating they occurred in independent cells.

To further evaluate the mechanisms of entrectinib resistance we engineered Ba/F3 cells to express ETV6-TRKA. In this model system the ETV6 domain mimics the dimerization effect of TRK fusion partners that occur in human tumors. Ba/F3 cells engineered to express ETV6-TRKA became exquisitely sensitive to entrectinib (Supplementary Fig.S2). ETV6-TRKA Ba/F3 cells were then exposed to entrectinib treatment until resistant derivatives emerged and analyzed as described above. Remarkably upon development of resistance Ba/F3 also acquired p.G595R mutation in the kinase domain of TRKA when a high dose of entrectinib was applied, while the p.G667C allele emerged in the presence of a lower dose of the drug (Supplementary Fig.S2). Analogously to what we observed in KM12, the two mutations were found in independent pools of Ba/F3 cells indicating they do not co-occur in the same cells.

\textit{NTRK1} p.G595R and p.G667C mutations drive resistance to TRK inhibitors
We then examined the impact of the p.G595R and p.G667C variants on the 3-dimensional (3D) structure of the TRKA catalytic domain (see Supplementary Methods). The binding model of entrectinib with wild type (WT) TRKA highlighted that entrectinib makes extensive hydrogen bonding as well as hydrophobic interactions with the protein in the ATP pocket where p.G595 and p.G667 residues are located (Fig. 3A). The p.G595R and p.G667C mutations create steric hindrance that either abrogates binding (p.G595R) or reduces the binding affinity (p.G667C) of entrectinib to the TRKA catalytic pocket (Fig. 3B,C respectively).

We next assessed whether and to what extent mutations in the kinase domain of NTRK1 drive resistance to TRKA inhibition. We engineered Ba/F3 cells expressing wild type, p.G595R or p.G667C TPM3-TRKA fusion proteins. We then measured the sensitivity of NTRK1 mutated cells to TRK inhibitors currently in clinical development. LOXO-101 is a TRK inhibitor in phase 1 trial for patients with advanced solid tumors with NTRK alterations (NCT02122913); TSR-011 is presently undergoing a phase 1 trial for patients with advanced solid tumors or lymphomas with NTRK alterations (NCT02048488).

As shown in Supplementary Fig.S3, Ba/F3 cells harboring the NTRK1 translocation become highly sensitive to TRK inhibitors (Supplementary Fig. S3 A,B; Supplementary Table S4). On the contrary NTRK1 p.G595R or p.G667C mutations are resistant to entrectinib, LOXO-101 and TSR-011 (Supplementary Fig. S3 C,D respectively). Of potential clinical relevance, and
in line with previous results, *NTRK1* p.G595R appears to be more potent in conferring resistance than p.G667C.

These results are indeed consistent with the observation that entrectinib and LOXO-101 retain a partial effect on p.G667C (IC$_{50}$=61 nM; IC$_{50}$= 524nM respectively) but are totally ineffective on p.G595R (IC$_{50}$>1000 nM) in Ba/F3 engineered cells (Supplementary Table S4).

Alignment of the TRKA kinase domain with clinically targeted tyrosine kinases, such as ALK, ROS, EGFR, MET and KIT, showed that the glycine residues at position 595 and 667 lie in a conserved region (Supplementary Fig. S4A and S4B respectively), and are analogous to residues previously found to be associated with secondary resistance to other kinase inhibitors such as erlotinib, crizotinib and imatinib (Fig.3D,E respectively).

**Biochemical characterization of *NTRK1* p.G595C and p.G667C in xenopatient derived cells.**

To mechanistically study the impact of *NTRK1* resistant alleles, we established two cell lines, one from the xenopatient treated with vehicle, and the other from the xenopatient that became resistant to entrectinib (Fig. 4A). Both cell lines displayed the *LMNA-NTRK1* translocation found in the patient tumor (Figure 4B), but only cells derived from the xenotumor that had become resistant to entrectinib carried the p.G595R allele (Figure 4C). Both cell lines displayed a pharmacological response to entrectinib analogous to that observed in the corresponding xenopatients (Fig.4D). Biochemical
characterization confirmed that NTRK1 secondary mutations render the corresponding proteins insensitive (or only marginally sensitive) to entrectinib and capable of activating downstream signaling in the presence of the drug (Fig. 4E, F). We next asked whether the tumor cell that had become resistant remained dependent on the expression of TRKA. Indeed, siRNA-mediated suppression of mutant NTRK1 in resistant cells induced apoptosis, similarly to the knockdown of WT NTRK1 in sensitive cells (Fig. 4G).

Discussion

A subset of CRCs carries NTRK1 translocations, which also occur in other tumor types such as lung tumors and thyroid carcinomas (6,13-15). The TRK inhibitor entrectinib induced a remarkable clinical response in a patient with a metastatic colorectal cancer carrying a LMNA-NTRK1 translocation, whose disease was intrinsically refractory to three prior lines of therapy including anti-EGFR inhibition(4) . However, after four months of treatment, resistance developed in this patient. The entrectinib half-life is 17-44h and the intermittent dosing regimen may have promoted or anticipated the development of resistance due to incomplete treatment coverage of the patient. Nevertheless, it is still unknown whether or not continuous dosing will affect the emergence and/or the type of acquired mutations.

In this work, we sought to identify mechanisms of resistance to entrectinib, as this is key to development of additional lines of therapy for patients carrying NTRK1 rearrangements. The most commonly used approach to study
resistance to targeted therapies involves molecular profiling of tissue biopsy obtained at progression. However, tumor heterogeneity and tissue sampling limit the effectiveness of this strategy. In addition, tissues biopsies are not always feasible and are associated with non-negligible risks (16). Most importantly, even when the biopsy reveals emergence of alleles that were not present before treatment, their functional role in driving resistance remains to be formally established using functional assays. This requires significant experimental efforts, and the timeframe is not compatible with further treatment of the patient from whom the biopsy was obtained. We find that coupling pharmacological analyses of xenopatients with molecular profiles of liquid biopsies allows the identification of resistance mechanisms in parallel with clinical treatment of individual patients, thus potentially enabling decisions on following treatment options.

We report for the first time that acquisition of p.G595R and p.G667C mutations in the kinase domain of TRKA drive secondary resistance to TRK inhibition in CRC cells carrying NTRK1 rearrangements. Both mutations were detected in patient plasma obtained at progression, suggesting that both are indeed associated with acquired resistance to entrectinib in the clinical setting. We found a remarkable concordance among results obtained in clinical samples and preclinical models. Genomic profiling of patient derived samples and multiple cell models pointed to the p.G595R or p.G667C NTRK1 mutations as the only common mechanism of resistance to entrectinib.
Analysis of a larger number of patients will ultimately be needed to determine the clinical impact of the findings. Based on data obtained with other anticancer therapies based on kinase inhibitors, it is possible that other mechanisms of resistance to entrectinib could occur, including activation of parallel pathways able to bypass TRKA inhibition.

Interestingly, we found that the emergence of each of the two mutations might be dependent on the entrectinib concentration used. *NTRK1* p.G667C emerged when cells were exposed to a low concentration of the inhibitor, while it was absent from cells made resistant to higher dose.

Structural model-based characterization also indicates that the potency of the p.G667C mutation in conferring resistance to entrectinib is weaker than p.G595R. Both mutations fall in the ATP binding pocket and are analogous to resistance mutations which have been described for other clinically druggable tyrosine kinase fusions. While p.G595C completely abrogates the binding of entrectinib to TRKA, the p.G667C only reduces affinity of binding. In line with this, homology alignment showed that TRKA p.G595R is analogous to ALK p.G1202R, while TRKA p.G667C to ALK p.G1269A. As for ALK p.G1269A which mediates resistance to crizotinib, this alteration can be overcome with second generation ALK inhibitors, such as ceritinib and alectinib, while both are ineffective on ALK p.G1202R(17-19); entrectinib at clinically achievable exposure still retain a partial effect on p.G667C but not on p.G595R TRKA.

Of note, while we found that cells that develop entrectinib’s resistance remain dependent on the expression of TRKA, none of the TRK inhibitors current being tested in the clinic (LOXO-101 and TSR-011) can overcome resistance
driven by p.G595R. Accordingly, the biochemical and pharmacological characterization of the preclinical models described here highlight the need of developing next generation TRKA inhibitors that do not rely on specific spatial accommodation of the drug-target interaction around G595 region, aimed at overcoming resistance driven by the p.G595R variant.

In addition to providing clues for the development of second generation TRK inhibitors, our finding offer means of tracking –non invasively- the emergence of resistance to entrectinib. Monitoring of NTRK1 resistant variants (p.G595R and p.G667C) in the plasma of patients treated with entrectinib could be valuable to predict recurrences.

**Material and Methods**

**Cells lines authentication**

KM12 CRC cells were obtained from NCI60 cell line bank and authenticated in May 2011. The genetic identity of cell line was last checked no less than three months before performing experiments by Cell ID™ System and by Gene Print® 10 System (Promega), throught Short Tandem Repeats (STR) at 10 different loci (D5S818, D13S317, D7S820, D16S539, D21S11, vWA, TH01, TPOX, CSF1PO and amelogenin). Amplicons from multiplex PCRs were separated by capillary electrophoresis (3730 DNA Analyzer, Applied Biosystems) and analyzed using GeneMapperID software from Life
Technologies. Cell lines were tested and resulted negative for mycoplasma contamination with Venor GeM Classic Kit (Minerva Biolabs).

Establishment of primary colorectal cancer cell line

Primary colorectal cancer cell lines were established from tumor tissues obtained from patient-derived xenografts. Tumor tissues were dissociated into single-cell suspension by mechanical dissociation using the gentleMACS Dissociator (Miltenyi Biotec) and enzymatic degradation of the extracellular matrix using the Tumor Dissociation Kit (Miltenyi Biotec) according to manufacturer’s instructions. The cell suspension was then centrifuged at 1200 rpm for 5 minutes. Supernatants were removed and cell pellets were resuspended with DMEM/F12 medium containing 10% FBS. This process was repeated 3 times. Then, cell suspensions were filtered through a 70µm cell strainer (Falcon) and resuspended with culture media DMEM-F12 containing 2 mM L-glutamine, antibiotics (100 U/mL penicillin and 100 µg/mL streptomycin), gentamicin 50 µg/ml and 10 µM ROCK inhibitor Y-27632 (Selleck Chemicals Inc.).

Ba/F3-TPM3-TRKA WT, G595R and G667C generation

To generate Ba/F3 cells expressing TPM3-TRKA WT, TPM3-TRKA G595R and TPM3-TRKA G667C the cDNAs were cloned from KM12 cells by RT-PCR and inserted into a lentiviral vector pVL-EF1a-MCS-IRE5-Puro (BioSettia, San Diego, CA). After confirmation by direct sequencing, VSVG-pseudo-typed lentiviruses were introduced into the murine IL-3 dependent pro-B cell Ba/F3. The transduced Ba/F3 cells were selected at 1 µg/mL of
puromycin in the murine IL-3 containing RPMI and 10% FBS media for two weeks. The stable cell pools were further selected in RPMI and 10% FBS media without murine IL-3 for 4 weeks.

**Drugs**

Entrectinib, LOXO-101(20) and TSR-011(21) were obtained from Ignyta, San Diego (CA, USA).

**Patient's samples collection**

Patient's plasma and tumor biopsy were obtained through protocols approved by local Ethical Committee at Ospedale Niguarda Ca' Granda, Milano, Italy. The study was conducted according to the provisions of the Declaration of Helsinki, and patient signed and provided his/her informed consent before sample collection. The liver biopsy was subcutaneously implanted in NOD-SCID mouse and experiments were performed according to a study protocol approved by Ethical Committee at Ospedale Niguarda Ca' Granda, Milano, Italy.

**Droplet digital PCR analysis**

Isolated circulating free DNA was amplified using ddPCR™ Supermix for Probes (Bio-Rad) with LMNA-NTRK1 translocation, NTRK1 p.G595R and NTRK1 p.G667C assays (sequences of custom designed probes are listed in Supplementary Table S5). ddPCR was then performed according to manufacturer’s protocol and the results reported as percentage or fractional abundance of mutant DNA alleles to total (mutant plus wild type) DNA alleles.
8–10 µl of DNA template was added to 10 µl of ddPCR Supermix for Probes (Bio-Rad) and 2 µl of the primer and probe mixture. This reaction mix was added to a DG8 cartridge together with 60 µl of Droplet Generation Oil for Probes (Bio-Rad) and used for droplet generation. Droplets were then transferred to a 96-well plate (Eppendorf) and then thermal cycled with the following conditions: 5 min at 95 °C, 40 cycles of 94 °C for 30 s, 55 °C for 1 min followed by 98 °C for 10 min (Ramp Rate 2 °C/s). Droplets were analyzed with the QX200 Droplet Reader (Bio-Rad) for fluorescent measurement of FAM and HEX probes. Gating was performed based on positive and negative controls, and mutant populations were identified. The ddPCR data were analyzed with QuantaSoft analysis software (Bio-Rad) to obtain fractional abundance of the mutated alleles in the wild-type or normal background. The quantification of the target molecule was presented as number of total copies (mutant plus WT) per sample in each reaction. The number of positive and negative droplets is used to calculate the concentration of the target and reference DNA sequences and their Poisson-based 95% confidence intervals, as previously shown(22). ddPCR analysis of normal control plasma DNA (from cell lines) and no DNA template controls were always included. Samples with too low positive events were repeated at least twice in independent experiments to validate the obtained results.

**Next Generation Sequencing analysis**

Libraries were prepared with Nextera Rapid Capture Custom Enrichment Kit (Illumina Inc., San Diego, CA, USA), according to the manufacturer’s protocol. Preparation of libraries was performed using up to 150ng of plasma ctDNA.
and 100 ng of gDNA from both cells and avatar fresh tissue. gDNA was fragmented using transposons, adding simultaneously adapter sequences. For ctDNA libraries preparation was used NEBNex® Ultra™ DNA Library Prep Kit for Illumina® (New England BioLabs Inc., Ipswich MA), with optimized protocol. Purified gDNA after the tagmentation step, and ctDNA were used as template for subsequent PCR to introduce unique sample barcodes. Fragments’ size distribution of the DNA was assessed using the 2100 Bioanalyzer with a High Sensitivity DNA assay kit (Agilent Technologies, Santa Clara, CA). Equal amount of DNA libraries were pooled and subjected to targeted panel hybridization capture. Libraries were then sequenced using Illumina MiSeq sequencer (Illumina Inc., San Diego, CA, USA).

Bioinformatic analysis

FastQ files generated by Illumina sequencer were mapped to the human reference (assembly hg19) using BWA-mem algorithm(23); PCR duplicates were then removed using the SAMtools package(24). Xenome software(25) was applied to remove murine sequences from xenopatient samples prior to alignment. We used a custom script pipeline for NGS in order to call somatic variations when supported by at least 1.5% allelic frequency and 5% significance level obtained with a Fisher's Test. Mutational analyses were the result of comparison between pre- and post-treatment samples.

Detection of LMNA-NTRK1 rearrangement in ctDNA

tDNA obtained from blood draw collected before entrectinib treatment started was analyzed by NGS as described above. To unveil the specific LMNA-
*NTRK1* genetic rearrangement, a combination of BWA (v. 0.7.10) and BLAT (v. 35) was used. BWA was first used to align reads to the hg19 human reference genome with default options. The reads with a non perfect alignment from BWA, potentially containing translocations, were extracted and aligned using BLAT (tileSize 11 and stepSize 5). The resulting PSL alignment was then post-processed to detect chimeric alignments. Gene fusion calling was performed using the following criteria: i) each fusion partner must have at least 25 mapped bases on the respective end of the read; ii) the fusion partners must map to two different genes; iii) each reported fusion breakpoint must be supported by at least 10 reads. Based on the fusion sequence identified by NGS analysis, specific ddPCR primers and probes for the *LMNA-NTRK1* rearrangement were designed using Primer3 Input (version 0.4.0) following BioRad instructions available on the website. Primers and probes sequences are listed in Supplementary Table S5.

**Kinase domain alignment**

The aminoacidic sequences of human TRKA [P04629], ALK [Q9UM73], ROS1 [P08922], EGFR [P00533], KIT [P10721] and MET [P08581] were obtained from UniprotKB database (26). Their kinase domains were aligned using the MUSCLE tool (27) and results were post-processed using Jalview (28).

**Acknowledgments**
Supported by the European Community's Seventh Framework Programme under grant agreement no. 602901, MErCuRIC (A.B.); Innovative Medicines Initiative grant no. 115749, CANCER-ID (A.B.) Associazione Italiana per la Ricerca sul Cancro (AIRC) IG grant no. 12812 (A.B.); AIRC 2010 Special Program Molecular Clinical Oncology 5 per mille, project no. 9970 (A.B.); FPRC 5 per mille 2010 and 2011 Ministero della Salute (F.D.N. and A.B.); Ministero dell’Istruzione, dell’Università e della Ricerca, progetto PRIN (A.B.). Investigators at Niguarda Cancer Center (ASB, SS) are also supported by Fondazione Oncologia Niguarda Onlus.

References


Figure Legends

Figure 1. Tracking resistance to TRKA inhibition in ctDNA of a CRC patient.

CT scans of a patient with metastatic colorectal cancer harboring an LMNA-NTRK1 rearrangement were recorded at baseline (March 2014), at the time of partial response to pan-TRK inhibitor entrectinib (April 2014) and upon disease progression (July 2014) (upper panels). Longitudinal analysis of plasma ctDNA collected at different time points throughout the treatment is shown in the lower panel. Red bars indicate absolute LMNA-NTRK1 copies in 1 ml of plasma; blue and black lines represent NTRK1 p.G595R and p.G667C mutated alleles (%), respectively. Average ± SD of 3 independent experiments is reported.
Figure 2. Resistance to entrectinib in xenopatient and CRC cell models carrying \textit{NTRK1} translocations. (A) Bioptic specimen obtained from a thin needle biopsy of a patient with metastatic colorectal cancer harboring an \textit{LMNA-NTRK1} rearrangement was first implanted subcutaneously in an immunocompromised mouse and then expanded in multiple mice upon successful engraftment. Mice were treated with dosage levels and schedules (60mg/kg, 4 days/week) that yielded clinically relevant exposure achievable in the patients. After 3 weeks of treatment a mouse (#4) in the treated arm relapsed. Blue and red lines indicate vehicle and entrectinib treated mice, respectively. (B) Proliferation assay of KM12 (carrying an \textit{TPM3-NTRK1} rearrangement) R1 cells made resistant to low dose entrectinib (300nM). Cell viability was assessed by measuring ATP content after 5 days of treatment. Sanger sequencing electropherogram of KM12 R1 shows \textit{NTRK1} p.G667C mutation. (C) Proliferation assay of KM12 (carrying an \textit{TPM3-NTRK1} rearrangement) R2 cells made resistant to a high dose of entrectinib (2µM). Cell viability was assessed by measuring ATP content after 5 days of treatment. Sanger sequencing electropherogram of KM12 R2 shows an \textit{NTRK1} p.G595R mutation.

Figure 3. 3D modeling and homology alignment of \textit{NTRK1} p.G595 and p.G667 variants

(A-C) Modeled binding mode of entrectinib with wildtype TRKA (A), TRKA p.G595R (B) and TRKA p.G667C (C). G595R and G667C mutants create steric hindrance directly with entrectinib, making it a much weaker binder with both mutants than the wild type. The alignments of amino acid sequences...
show that NTRK1 mutation p.G595 (D) and p.G667 (E) are conserved among 6 clinically relevant tyrosine kinases listed in the figure. Both alterations are located in a residue homologous to amino acids changes involved in acquired resistance to therapies targeting other tyrosine kinases.

**Figure 4. Biochemical and pharmacological characterization of xenopatient derived CRC cells.**

(A) CRC cells were established from a vehicle treated xenopatient (sensitive to entrectinib) and from the tumor grown in xenopatient #4 that became resistant to entrectinib treatment in vivo. (B) Sanger sequencing electropherogram shows LMNA-NTRK1 genetic rearrangements in both xenopatient-derived cell lines. (C) Cells derived from the xenopatient that developed resistance to entrectinib display NTRK1 p.G595R mutation. (D) Drug proliferation assay of LMNA-NTRK1 rearranged CRC cells. Entrectinib sensitive cells established from vehicle treated xenopatient are indicated with black line; entrectinib resistant cells established from resistant xenopatient are indicated with red line. Cell viability was assessed by measuring ATP content after 5 days of treatment. (E) Sensitive and resistant xenopatient-derived cells were treated with 1 µM entrectinib for 16h; after that, protein lysates were analyzed by western blot. (F) Sensitive and resistant xenopatient-derived cells were treated with 1 µM entrectinib for 48h; after that, protein lysates were analyzed by western blot. (G) RNAi knockdown of WT NTRK1 in xenopatient derived sensitive cells and mutated NTRK1 in xenopatient derived resistant cells induces apoptosis as shown by cleaved PARP. Protein lysates were
analyzed by western blot 3 days after transfection with NTRK1-specific pooled siRNAs, scrambled siRNA, or transfection reagent (mock).
A

WT TRKA - entrectinib

B

TRKA G595R - entrectinib

C

TRKA G667C - entrectinib

D

<table>
<thead>
<tr>
<th>Gene</th>
<th>Codon</th>
<th>Mutation at resistance</th>
<th>Tissue of detection</th>
<th>Associated with Resistance to</th>
</tr>
</thead>
<tbody>
<tr>
<td>NTRK1</td>
<td>595</td>
<td>p.G595R</td>
<td>Colon</td>
<td>Entrectinib</td>
</tr>
<tr>
<td>ALK</td>
<td>1202</td>
<td>p.G1202R</td>
<td>Lung</td>
<td>Crizotinib/Ceritinib</td>
</tr>
<tr>
<td>ROS1</td>
<td>2032</td>
<td>p.G2032R</td>
<td>Lung</td>
<td>Crizotinib</td>
</tr>
<tr>
<td>EGFR</td>
<td>796</td>
<td>p.G796A/R</td>
<td>Lung</td>
<td>Erlotinib/Gefitinib</td>
</tr>
</tbody>
</table>

E

<table>
<thead>
<tr>
<th>Gene</th>
<th>Codon</th>
<th>Mutation at resistance</th>
<th>Tissue of detection</th>
<th>Associated with Resistance to</th>
</tr>
</thead>
<tbody>
<tr>
<td>NTRK1</td>
<td>667</td>
<td>p.G667C</td>
<td>Colon</td>
<td>Entrectinib</td>
</tr>
<tr>
<td>ALK</td>
<td>1269</td>
<td>p.G1269A</td>
<td>Lung</td>
<td>Crizotinib</td>
</tr>
<tr>
<td>ROS1</td>
<td>2101</td>
<td>p.G2101A</td>
<td>Lung</td>
<td>Crizotinib</td>
</tr>
<tr>
<td>EGFR</td>
<td>854</td>
<td>p.T854A</td>
<td>Lung</td>
<td>Erlotinib/Gefitinib</td>
</tr>
<tr>
<td>KIT</td>
<td>809</td>
<td>p.C809G</td>
<td>GIST</td>
<td>Imatinib</td>
</tr>
</tbody>
</table>
Acquired resistance to the TRK inhibitor entrectinib in colorectal cancer

Mariangela Russo, Sandra Misale, Ge Wei, et al.

Cancer Discov Published OnlineFirst November 6, 2015.